Italia markets closed

Certara, Inc. (CERT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
17,56-2,63 (-13,03%)
Alla chiusura: 04:00PM EDT
17,30 -0,26 (-1,48%)
Dopo ore: 07:59PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente20,19
Aperto16,99
Denaro17,00 x 4000
Lettera18,68 x 900
Min-Max giorno16,73 - 17,70
Intervallo di 52 settimane16,17 - 45,48
Volume6.876.885
Media Volume611.616
Capitalizzazione2,808B
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-0,09
Prossima data utili07 nov 2022 - 11 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A25,21
  • GlobeNewswire

    Certara Announces Secondary Offering

    PRINCETON, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) (“Certara”), a global leader in biosimulation, today announced the sale by certain stockholders (the “Selling Stockholders”), including EQT Avatar Parent L.P., in an underwritten secondary offering of 7,000,000 shares of common stock of Certara pursuant to a registration statement filed by Certara with the U.S. Securities and Exchange Commission (the “SEC”). In connection with the offering, the Selling Stockholders h

  • GlobeNewswire

    Certara Reports Second Quarter 2022 Financial Results

    Biosimulation software and services fuel second quarter growthPRINCETON, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2022 and adjusted its full year guidance. Second Quarter Highlights: Revenue was $82.8 million, compared to $70.1 million in the second quarter of 2021, representing growth of 18% over the second quarter of 2021 on a reported basis and 21% at const

  • GlobeNewswire

    Certara Introduces Update of Pinnacle 21™ Enterprise and New Pinnacle 21™ Data Exchange Module

    New automation, analytics and collaboration features save time and ensure regulatory compliance PRINCETON, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release 5.2.0 of Pinnacle 21 Enterprise, the Company’s flagship software for validating clinical trial data for biosimulation and regulatory submissions. It also introduced the new Pinnacle 21 Data Exchange product, an integrated module that streamlines the pro